Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996

TerminatedPhase 3

Sponsor: Genentech, Inc.

Conditions: Rheumatoid Arthritis

Interventions: Leflunomide, Methotrexate, Ocrelizumab, Ocrelizumab, Placebo

Countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy. Patients will be randomized to receive placebo, 200mg of intravenous ocrelizumab, or 500mg of i.v. ocrelizumab on days 1 and 15. A repeat course of i.v. treatment will be administered at weeks 24 and 26. All patients will receive stable doses of either concomitant methotrexate (7.5-25mg/week) or leflunomide (10-20mg po daily) and may receive additional DMARDs. The treatment period is planned for 48 weeks (until primary analysis) and then participants will enter the open label phase until the drug is commercialized. Target sample size is 1000.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Adult patients, ≥ 18 years of age
* Rheumatoid arthritis for at least 3 months
* Inadequate response to previous or current treatment with at least one anti-TNF-alpha agent
* Receiving either leflunomide or methotrexate for ≥ 12 weeks, with a stable dose for the last 4 weeks
* Swollen joint count (SJC) ≥ 4 (66 joint count) and tender joint count (TJC) ≥ 4 (68 joint count) at screening and baseline.
* CRP ≥ 0.6 mg/dL using a high-sensitivity assay.
* Positive rheumatoid factor or positive anti-CCP antibody or both.

Exclusion Criteria:

* Rheumatic autoimmune disease or inflammatory joint disease, other than RA
* Any surgical procedure in past 12 weeks,or planned within 48 weeks of baseline
Locations (266)
  • Anniston, Alabama, United States
  • Birmingham, Alabama, United States
  • Huntsville, Alabama, United States
  • Mesa, Arizona, United States
  • Mesa, Arizona, United States
  • Tucson, Arizona, United States
  • Tucson, Arizona, United States
  • Hot Springs, Arkansas, United States
  • Little Rock, Arkansas, United States
  • La Jolla, California, United States
  • Long Beach, California, United States
  • Los Alamitos, California, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
  • Palo Alto, California, United States
  • San Diego, California, United States
  • San Diego, California, United States
  • San Leandro, California, United States
  • Torrance, California, United States
  • Aurora, Colorado, United States
  • Colorado Springs, Colorado, United States
  • Camden, Connecticut, United States
  • Trumbull, Connecticut, United States
  • Lewes, Delaware, United States
  • Newark, Delaware, United States
  • Aventura, Florida, United States
  • Jacksonville, Florida, United States
  • Palm Harbor, Florida, United States
  • Palm Harbor, Florida, United States
  • Sarasota, Florida, United States
  • + 236 more on CT.gov